

## Anti-Golden Syrian Hamster IgG F(ab')2 (Alkaline Phosphatase Conjugated) Secondary Antibody

Rabbit Polyclonal, Alkaline Phosphatase (Calf Intestine) Catalog # ASR2683

## **Product Information**

**Description** Anti-GOLDEN SYRIAN HAMSTER IgG F(ab')2 (RABBIT) Antibody Alkaline

Phosphatase Conjugated

**Host** Rabbit

**Conjugate** Alkaline Phosphatase (Calf Intestine)

**Target Species** Golden Syrian Hamster

**Clonality** Polyclonal

Physical State Liquid (sterile filtered)

Host Isotype IgG

**Target Isotype** IgG F(ab')2

**Buffer** 0.05 M Tris Chloride, 0.15M Sodium Chloride, 0.001M Magnesium Chloride,

0.0001M Zinc Chloride, 50% (v/v) Glycerol; pH 8.0

**Immunogen** Hamster IgG F(ab')2 fragment

Stabilizer 10 mg/mL Bovine Serum Albumin (BSA) - Immunoglobulin and Protease free

**Preservative** 0.01% (w/v) Sodium Azide

## **Additional Information**

Shipping Condition Wet Ice

**Application Note** This product has been assayed against 1.0 ug of Hamster IgG in a standard

capture ELISA using pNPP p-nitrophenyl phosphate code # NPP-10 as a substrate for 30 minutes at room temperature. A working dilution of 1:1,000 to 1:5,000 of the reconstitution concentration is suggested for this product.

**Purity** This product was prepared from monospecific antiserum by immunoaffinity

chromatography using Hamster IgG coupled to agarose. Assay by

immunoelectrophoresis resulted in a single precipitin arc against anti-Alkaline Phosphatase (calf intestine), anti-Rabbit Serum, Hamster IgG and Hamster

Serum. No reaction was observed against Hamster IgG F(c).

**Storage Condition** Store vial at 4° C before opening. DO NOT FREEZE. This product is stable at

4° C as an undiluted liquid. Dilute only prior to immediate use. Freezing alkaline phosphatase conjugates will result in a substantial loss of enzymatic

activity.

**Precautions Note**This product is for research use only and is not intended for therapeutic or

diagnostic applications.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.